A phase I/II trial of VR-CHOP [bortezomib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone] for patients with untreated follicular lymphoma and other low grade B-cell lymphomas.
Phase of Trial: Phase I/II
Latest Information Update: 29 Oct 2016
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 14 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Feb 2015 to 1 Dec 2015.
- 05 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed to 1 Dec 2015.